Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210 |
T: 617.570.1000
goodwinprocter.com
|
Attention:
|
Joseph Ambrogi
Maryse Mills-Apenteng
|
Re: |
Arrowroot Acquisition Corp.
Preliminary Proxy Statement on Schedule 14A Filed February 2, 2023 File No. 001-40129 |
1.
|
With a view toward disclosure, please tell us whether your sponsor is, is controlled by, has any members who are, or has substantial ties with, a
non-U.S. person. Also revise your filing to include risk factor disclosure that addresses how this fact could impact your ability to complete your initial business combination. For instance, discuss the risk to investors that you may not be
able to complete an initial business combination with target company should the transaction be subject to review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (CFIUS), or ultimately
prohibited. Disclose that as a result, the pool of potential targets with which you could complete an initial business combination may be limited. Further, disclose that the time necessary for government review of the transaction or a
decision to prohibit the transaction could prevent you from completing an initial business combination and require you to liquidate. Disclose the consequences of liquidation to investors, such as the losses of the investment opportunity in
a target company, any price appreciation in the combined company, and the warrants, which would expire worthless.
|
Sincerely,
|
|
/s/ Jocelyn Arel
|
|
Goodwin Procter LLP
|